Fireside Chat: Accelerating 14C Human ADME by Integrated Radiosynthesis, GMP Manufacture, and Clinical Delivery

Basel, Switzerland | 1 July 2026
Overview

Fireside Chat: Accelerating 14C Human ADME by Integrated Radiosynthesis, GMP Manufacture, and Clinical Delivery  

Join us for an exclusive rooftop drinks reception at the Bohemia Restaurant, Hotel Märthof Basel, featuring a relaxed fireside chat and networking.

Set on the terrace, this informal evening will bring together peers and experts to explore how an integrated Synthesis-to-Clinic® approach can simplify and accelerate the delivery of ¹⁴C human ADME studies—reducing reliance on multiple vendors while maintaining the high-quality outputs required for global regulatory submissions.

Through an engaging fireside discussion, Quotient Sciences’ experts will share how their end-to-end model—spanning radiosynthesis, GMP manufacture, clinical conduct, mass balance, metabolite profiling, and reporting—addresses the complexity and timelines typically associated with ADME programmes.

Attendees will gain practical insights into how integrated delivery can streamline execution, de-risk development, and accelerate pathways to NDA and MAA submissions.

Key learning objectives  

By the end of this seminar, attendees should be able to:  

  • Understand the various applications of 14C enabled drug development including human ADME and ivMicrotracers  
  • Explain why and when human ADME studies are needed within development programs and how earlier execution can reduce regulatory and program risk
  • Describe the core regulatory drivers and considerations shaping radiolabeled mass balance/human ADME expectations
  • Identify the critical design inputs for a human ADME program (safety/PK, non-clinical metabolism data, synopsis development, radiolabelled API needs, and drug product considerations across oral/IV dosing 
  • Compare conventional ADME vs microADME approaches and understand when microADME (≤1 µCi, no dosimetry requirement) may be appropriate  
  • Learn about the key analytical challenges associated with 14C driven programs  
Date/TimeLocation
Wednesday, July 1, 2026
18:00 CET

Bohemia Bar - Hotel Märthof Basel

MARKTGASSE 19 | CH-4051 BASEL – SCHWEIZ 

TimeAgenda
 18:00 – 18:30

Welcome drinks:  

Opening Remarks
John McDermott, Quotient Sciences 

18:30 – 19:30Panel Discussion & Audience Q&A

Interactive discussion across speakers, including case study insights and audience questions  
19:30 – 19:45Closing Remarks

Summary of key takeaways and final reflections
19:45 onwardsNetworking Reception & Drinks

Opportunity for further discussion with speakers and peers  

Space is limited! Register your interest to attend our seminar. If you have any questions or difficulty registering, reach out to [email protected].

 

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register
Location
Bohemia Bar - Hotel Märthof Basel
MARKTGASSE 19 | CH-4051 BASEL – SCHWEIZ
Basel, Switzerland

Meet our experts:

We look forward to meeting you at the Fireside Chat: Synthesis-to-Clinic®: Accelerating 14C Human ADME by Integrated radiosynthesis, GMP manufacture, and Clinical Delivery in July.

John McDermott

VP, Scientific Consulting

John McDermott leads Quotient Sciences' global drug development consulting, research fellows, modeling & simulation, and clien...

About John
Iain Shaw

Senior Director, 14C Enabled Drug Development

Iain Shaw has over 30 years of experience in the pharmaceutical industry, including over 15 years focused on 14C-enabled drug deve...

About Iain
Eleanor Row, PhD

VP, Scientific Consulting & Project Management - Arcinova

Eleanor Row brings over 20 years of experience in the pharmaceutical and contract research sectors, having worked with leading mul...

About Eleanor
Let's Talk
Humanity can't wait, so neither can we. Discuss your drug program today.